All In MedTech

Device Trial Radar · NCT06710873

Analysis of Clinical Application of China's First Batch of TYRX Absorbable Antibacterial Envelope

Last checked: Nov 19, 2026Latest source record: Mar 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

50

Actual

Start

Dec 1, 2023

Primary completion

Oct 9, 2024

Study completion Mar 1, 2026

Sponsor

Lead sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 29, 2024

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 18 years

Summary

As written by the sponsor on the registry.

This study is the first to use TYRX domesticly, reporting and summarizing its usage to validate its real-world effectiveness in CIED infection prevention.

Conditions

  • CIED Infection
  • TYRX Absorbable Antibacterial Envelope

Interventions

  • TYRX Absorbable Antibacterial EnvelopeDevice

    All enrolled patients will receive the TYRX Absorbable Antibacterial Envelope implanted simultaneously during the CIED surgery.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CIED infectionTime frame: three months post-surgery

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun-Yatsen Memorial Hospital of Sun-Yatsen University

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.